Photoactivatable CRISPR-Cas9 for optogenetic genome editing

  title={Photoactivatable CRISPR-Cas9 for optogenetic genome editing},
  author={Yuta Nihongaki and Fuun Kawano and Takahiro Nakajima and Moritoshi Sato},
  journal={Nature Biotechnology},
We describe an engineered photoactivatable Cas9 (paCas9) that enables optogenetic control of CRISPR-Cas9 genome editing in human cells. [] Key Result In response to blue light irradiation, paCas9 expressed in human embryonic kidney 293T cells induces targeted genome sequence modifications through both nonhomologous end joining and homology-directed repair pathways. Genome editing activity can be switched off simply by extinguishing the light.

Optical Control of Genome Editing by Photoactivatable Cas9.

A detailed protocol for optogenetic genome editing experiments using photoactivatable Cas9 is provided, including that for the generation of guide RNA vectors, light-mediated Cas9 activation, and quantification of genome editing efficiency in mammalian cells.

Chemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering.

Recent advancements to modulate Cas9-mediated genome editing by engineering split-Cas9 constructs, inteins, small molecules, protein-based dimerizing domains, and light-inducible systems are reviewed.

Optogenetics and CRISPR: A New Relationship Built to Last.

An overview of the state-of-the-art methods for light-control of CRISPR effectors and the plethora of exciting applications enabled by these systems, including spatially confined genome editing, timed activation of endogenous genes, as well as remote control of chromatin-chromatin interactions are detailed.

Optical control of CRISPR-Cas editing with cyclically caged guide RNAs

A spatiotemporal and efficient CRISPR/Cas9 and Cpf1-mediated editing with photo-sensitive circular gRNAs that achieves light-mediated MSTN gene editing in embryos and a new bow-knot-type gRNA showed no background editing in the absence of light irradiation.

Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein

This work reports the first optogenetic tool to control NmeCas9 activity in mammalian cells via an engineered, light-dependent anti-CRISPR (Acr) protein and demonstrates optogenetics regulation of a type II-C CRISPR effector and might suggest a new route for the design of optogenetically Acrs.

Precise and efficient scarless genome editing in stem cells using CORRECT

This protocol outlines in detail how to implement either the re-Guide or re-Cas variants of CORRECT to generate scarlessly edited isogenic stem cell lines with intended monoallelic and biallelic sequence changes in ∼3 months.

Programmable Live‐Cell CRISPR Imaging with Toehold‐Switch‐Mediated Strand Displacement

A toehold-switch-based approach to engineer the conformation of single guide RNA (sgRNA) for programmable activation of Cas9 and provides a new route for programing CRISPR in living cells for genome imaging and engineering.

Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light-Activated Guide RNA

A new method for conditional regulation of CRISPR/Cas9 activity in mammalian cells and zebrafish embryos via photochemically activated, caged guide RNAs, enabling the investigation of spatiotemporally complex physiological events by obtaining a better understanding of dynamic gene regulation.

Programmable live-cell CRISPR imaging with toehold switch-mediated strand displacement reactions.

A toehold switch-based approach to engineer the conformation of single guide RNA (sgRNA) for programmable activation of Cas9 with orthogonal DNA inputs is reported, which provides a new route to program CRISPR in living cells for genome imaging and engineering.

CRISPR/Cas9 for Human Genome Engineering and Disease Research.

The broad application of this system to the study of functional genomics, especially genome-wide genetic screening, and to therapeutics development, including establishing disease models, correcting defective genetic mutations, and treating diseases are discussed.



Inducible in vivo genome editing with CRISPR/Cas9

It is shown that doxycycline-regulated Cas9 induction enables widespread gene disruption in multiple tissues and that limiting the duration of Cas9 expression or using a Cas9D10A (Cas9n) variant can regulate the frequency and size of target gene modifications, respectively.

A light-inducible CRISPR/Cas9 system for control of endogenous gene activation

A light-activated CRISPR/Cas9 effector (LACE) system that induces transcription of endogenous genes in the presence of blue light is engineered by fusing the light-inducible heterodimerizing proteins CRY2 and CIB1 to a transactivation domain and the catalytically inactive dCas9, respectively.

A split-Cas9 architecture for inducible genome editing and transcription modulation

It is demonstrated that Cas9 can be split into two fragments and rendered chemically inducible by rapamycin sensitive dimerization domains for controlled reassembly to mediate genome editing and transcription modulation.

Multiplex Genome Engineering Using CRISPR/Cas Systems

Two different type II CRISPR/Cas systems are engineered and it is demonstrated that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells, demonstrating easy programmability and wide applicability of the RNA-guided nuclease technology.

RNA-programmed genome editing in human cells

It is shown here that Cas9 assembles with hybrid guide RNAs in human cells and can induce the formation of double-strand DNA breaks at a site complementary to the guide RNA sequence in genomic DNA.

RNA-Guided Human Genome Engineering via Cas9

The type II bacterial CRISPR system is engineer to function with custom guide RNA (gRNA) in human cells to establish an RNA-guided editing tool for facile, robust, and multiplexable human genome engineering.

Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins

Delivery of purified recombinant Cas9 protein and guide RNA into cultured human cells including hard-to-transfect fibroblasts and pluripotent stem cells is delivered and RGEN ribonucleoproteins (RNPs) induce site-specific mutations at frequencies of up to 79%, while reducing off- target mutations associated with plasmid transfection at off-target sites.